[Clinical evaluation of the preparations Baycuten and Baycuten SD produced by Bayer].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002701:Chloramphenicol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003022:Clotrimazole / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012871:Skin Diseases / Q000188:drug therapy*; D012874:Skin Diseases, Infectious / Q000188:drug therapy
D004338:Drug Combinations; D007093:Imidazoles; C034415:azidamfenicol, clotrimazole drug combination; C017051:azidoamphenicol, clotrimazole, dexamethasone drug combination; D002701:Chloramphenicol; D003907:Dexamethasone; D003022:Clotrimazole
Kliniczna ocena preparatów Baycuten i Baycuten SD firmy Bayer.